Jim Cramer’s Recent Thoughts on These 15 Stocks

Page 3 of 14

12. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 15

Upon receiving a caller’s inquiry about ImmunityBio, Inc. (NASDAQ:IBRX), Cramer stated:

“IBRX is not a great stock, immunity bio. I’ve looked at it for a very, very long time. I don’t like the fact that they are, they’ve been losing money forever. I am not in their camp.”

ImmunityBio. (NASDAQ:IBRX) develops advanced immunotherapies targeting cancer and infectious diseases, focusing on cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. Its lead candidate, Anktiva, is FDA-approved for use with bacillus calmette-guérin in treating certain bladder cancers.

On May 20, Piper Sandler raised its rating on ImmunityBio (NASDAQ:IBRX) to Overweight from Neutral and increased the price target to $5 from $4.25. The firm highlighted the company’s work on Anktiva, t-haNK, and M-ceNK cell therapies, and DNA vaccines aimed at reactivating the immune system to fight cancer. Anktiva has shown a strong start in treating non-muscle invasive bladder cancer, with projected sales of $83.5 million in 2025. Piper believes there is potential for broader use of Anktiva, despite the FDA’s refusal to file a letter for one of its bladder cancer indications.

Page 3 of 14